Ursolic acid
Based on 20 publication(s) in Google Scholar
Ursolic acid (Prunol) is a natural pentacyclic triterpenoid carboxylic acid, exerts anti-tumor effects and is an effective compound for cancer prevention and therapy.
For research use only. We do not sell to patients.
- Purity: 99.02%
- CAS No.: 77-52-1
- Formula: C30H48O3
- Molecular Weight:456.70
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) Ursolic acid
More- Chem Eng J. 2025 Nov 7;525:170493.
- J Hazard Mater. 2026 Mar 15:506:141417. [Abstract]
- Int J Biol Sci. 2023 Aug 15;19(13):4242-4258. [Abstract]
- Food Chem. 2023 Mar 30;405(Pt A):134807. [Abstract]
- Cell Death Dis. 2018 Aug 28;9(9):847. [Abstract]
- Phytomedicine. 2025 Dec 24:150:157740. [Abstract]
- Phytomedicine. 2025 May:140:156484. [Abstract]
- Brain Behav Immun. 2020 Nov;90:108-137. [Abstract]
- PLoS Biol. 2024 Jun 27;22(6):e3002672. [Abstract]
- Int J Mol Sci. 2026 Mar 11;27(6):2587. [Abstract]
- Eur J Pharmacol. 2024 Aug 13:176896. [Abstract]
- Int Immunopharmacol. 2022 Dec;113(Pt A):109321. [Abstract]
- Cancers (Basel). 2023 Apr 20;15(8):2378. [Abstract]
- Sci Rep. 2025 Jul 1;15(1):21623. [Abstract]
- J King Saud Univ Sci. 2025 Oct 6.
- J Immunol Res. 2021 Apr 30:2021:6679316. [Abstract]
- Toxicon. 2025 Jan 7:108233. [Abstract]
- Animal Research and One Health. 2025 Nov 12.
- bioRxiv. 2024 Apr 3:2023.06.02.542933. [Abstract]
- Research Square Print. December 12th, 2022.
-
Cell Proliferation/Viability Assay
-
Histological Imaging/Staining
-
WB
-
Apoptosis Analysis
-
Flow Cytometry
All Endogenous Metabolite Isoforms
More
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 4T1 | IC50 |
44.08 μM
Compound: 2; UA
|
Cytotoxicity activity against mouse 4T1 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity activity against mouse 4T1 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 30433783] |
| 518A2 | EC50 |
14.7 μM
Compound: 1
|
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
|
[PMID: 28033541] |
| 518A2 | EC50 |
14.7 μM
Compound: 2; UA
|
Cytotoxicity against human 518A2 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
Cytotoxicity against human 518A2 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
|
[PMID: 27149037] |
| 518A2 | EC50 |
14.7 μM
Compound: UA
|
Cytotoxicity against human 518A2 cells assessed as cell survival after 96 hrs by SRB assay
Cytotoxicity against human 518A2 cells assessed as cell survival after 96 hrs by SRB assay
|
[PMID: 26177446] |
| 518A2 | EC50 |
14.7 μM
Compound: UA
|
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
|
[PMID: 26750249] |
| 8505C | EC50 |
13.5 μM
Compound: 1
|
Cytotoxicity against human 8505C cells after 96 hrs by SRB assay
Cytotoxicity against human 8505C cells after 96 hrs by SRB assay
|
[PMID: 28033541] |
| 8505C | EC50 |
13.5 μM
Compound: UA
|
Cytotoxicity against human 8505C cells assessed as cell survival after 96 hrs by SRB assay
Cytotoxicity against human 8505C cells assessed as cell survival after 96 hrs by SRB assay
|
[PMID: 26177446] |
| A2780 | EC50 |
11.7 μM
Compound: 1
|
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
|
[PMID: 28033541] |
| A2780 | EC50 |
11.7 μM
Compound: 2; UA
|
Cytotoxicity against human A2780 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
Cytotoxicity against human A2780 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
|
[PMID: 27149037] |
| A2780 | EC50 |
11.7 μM
Compound: UA
|
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
|
[PMID: 26750249] |
| A2780 | EC50 |
11.7 μM
Compound: UA
|
Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
|
[PMID: 31718946] |
| A2780 | IC50 |
>=20 μg/mL
Compound: 11
|
Cytotoxicity against human A2780 cells
Cytotoxicity against human A2780 cells
|
[PMID: 12662105] |
| A2780 | IC50 |
9.2 μg/mL
Compound: ursolic acid
|
Cytotoxicity against human A2780 cells
Cytotoxicity against human A2780 cells
|
[PMID: 15217279] |
| A-375 | IC50 |
30.88 μM
Compound: 2; UA
|
Cytotoxicity activity against human A375 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity activity against human A375 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 30433783] |
| A549 | EC50 |
15.5 μM
Compound: 1
|
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
|
[PMID: 28033541] |
| A549 | EC50 |
15.5 μM
Compound: 2; UA
|
Cytotoxicity against human A549 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
Cytotoxicity against human A549 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
|
[PMID: 27149037] |
| A549 | EC50 |
15.5 μM
Compound: UA
|
Cytotoxicity against human A549 cells assessed as cell survival after 96 hrs by SRB assay
Cytotoxicity against human A549 cells assessed as cell survival after 96 hrs by SRB assay
|
[PMID: 26177446] |
| A549 | EC50 |
15.5 μM
Compound: UA
|
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
|
[PMID: 26750249] |
| A549 | IC50 |
11.4 μM
Compound: 1
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 22959527] |
| A549 | IC50 |
16 μM
Compound: 1; UA
|
Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by Hoechst 33258 staining based fluorescence assay
Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by Hoechst 33258 staining based fluorescence assay
|
[PMID: 38718553] |
| A549 | IC50 |
18.42 μM
Compound: 2; UA
|
Cytotoxicity activity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity activity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 30433783] |
| A549 | IC50 |
21.6 μM
Compound: 3
|
Antiinflammatory activity against human A549 cells assessed as inhibition of IL-1-alpha-induced ICAM1 expression treated after 1 hr before IL1alpha challenge
Antiinflammatory activity against human A549 cells assessed as inhibition of IL-1-alpha-induced ICAM1 expression treated after 1 hr before IL1alpha challenge
|
[PMID: 15730243] |
| A549 | IC50 |
33 μM
Compound: 1
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 26854375] |
| A549 | IC50 |
33 μM
Compound: 4
|
Growth inhibition of human A549 cells after 48 hrs by sulforhodamine-B assay
Growth inhibition of human A549 cells after 48 hrs by sulforhodamine-B assay
|
[PMID: 23811086] |
| A549 | IC50 |
35.79 μM
Compound: UA
|
Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 25841199] |
| A549 | IC50 |
35.79 μM
Compound: UA; 1
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 30108853] |
| A549 | IC50 |
55.8 μM
Compound: 3
|
Cytotoxicity against human A549 cells assessed as cell viability after 24 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as cell viability after 24 hrs by MTT assay
|
[PMID: 15730243] |
| A549 | IC50 |
74.65 μM
Compound: UA
|
Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay
Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay
|
[PMID: 26343825] |
| A549 | IC50 |
77.65 μM
Compound: 2; UA
|
Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 31673307] |
| AGS | IC50 |
20.6 μM
Compound: 1, UA, Ursolic acid
|
Cytotoxicity against human AGS cells after 48 hrs by MTT assay
Cytotoxicity against human AGS cells after 48 hrs by MTT assay
|
[PMID: 22370266] |
| AGS | IC50 |
20.6 μM
Compound: UA 5
|
Cytotoxicity in human AGS cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity in human AGS cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 28754470] |
| AGS | IC50 |
43.3 μM
Compound: UA 5
|
Cytotoxicity in human AGS cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity in human AGS cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 28754470] |
| ASPC1 | IC50 |
12.6 μM
Compound: 1
|
Cytotoxicity against human AsPC1 cells after 72 hrs by MTT assay
Cytotoxicity against human AsPC1 cells after 72 hrs by MTT assay
|
[PMID: 22959527] |
| B16 | IC50 |
3.1 μM
Compound: 23
|
Growth inhibition of mouse B16 2F2 cells after 3 days
Growth inhibition of mouse B16 2F2 cells after 3 days
|
[PMID: 12027734] |
| B16-F10 | IC50 |
20.08 μM
Compound: 2; UA
|
Cytotoxicity activity against mouse B16F10 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity activity against mouse B16F10 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 30433783] |
| Bcap37 | IC50 |
28.69 μM
Compound: 1, UA, Ursolic acid
|
Antiproliferative activity against human Bcap37 cells after 72 hrs by MTT assay
Antiproliferative activity against human Bcap37 cells after 72 hrs by MTT assay
|
[PMID: 23124210] |
| Bel-7402 | IC50 |
64.64 μM
Compound: 2; UA
|
Cytotoxicity against human Bel7402 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human Bel7402 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 31673307] |
| BGC-823 | IC50 |
>10 μM
Compound: 1, Ursolic acid,UA
|
Antiproliferative activity against human BGC823 cells after 96 hrs by MTT assay
Antiproliferative activity against human BGC823 cells after 96 hrs by MTT assay
|
[PMID: 19091579] |
| BGC-823 | IC50 |
22.96 μM
Compound: UA, Ursolic acid
|
Cytotoxicity against human BGC823 cells by MTT assay
Cytotoxicity against human BGC823 cells by MTT assay
|
[PMID: 21664827] |
| BGC-823 | IC50 |
66.38 μM
Compound: 1, UA, Ursolic acid
|
Cytotoxicity against human BGC823 cells after 24 hrs by MTT assay
Cytotoxicity against human BGC823 cells after 24 hrs by MTT assay
|
[PMID: 21514015] |
| Ca9-22 | IC50 |
5.9 μg/mL
Compound: 8
|
Cytotoxicity against human Ca9-22 cells after 24 hrs by MTT assay
Cytotoxicity against human Ca9-22 cells after 24 hrs by MTT assay
|
[PMID: 19534471] |
| CAPAN-1 | IC50 |
8.6 μM
Compound: UA
|
Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay
Antiproliferative activity against human CAPAN-1 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay
|
[PMID: 34352711] |
| CEM-SS | CC50 |
21.9 μM
Compound: 6
|
Cytotoxicity against human CEM-SS cells after 6 days by MTS assay
Cytotoxicity against human CEM-SS cells after 6 days by MTS assay
|
[PMID: 15217281] |
| CHO | EC50 |
1.43 μM
Compound: 3
|
Agonist activity at TGR5 expressed in CHO cells by CRE-driven luciferase reporter gene assay
Agonist activity at TGR5 expressed in CHO cells by CRE-driven luciferase reporter gene assay
|
[PMID: 19911773] |
| COS-1 | EC50 |
0 μM
Compound: 3
|
Agonist activity at human FXR expressed in COS1 cells by luciferase reporter gene assay
Agonist activity at human FXR expressed in COS1 cells by luciferase reporter gene assay
|
[PMID: 19911773] |
| DLD-1 | IC50 |
16 μM
Compound: 1; UA
|
Cytotoxicity against human DLD-1 cells assessed as inhibition of cell growth measured after 48 hrs by Hoechst 33258 staining based fluorescence assay
Cytotoxicity against human DLD-1 cells assessed as inhibition of cell growth measured after 48 hrs by Hoechst 33258 staining based fluorescence assay
|
[PMID: 38718553] |
| DU-145 | IC50 |
11.1 μg/mL
Compound: 1
|
Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
|
[PMID: 30057155] |
| Epithelial cell | IC50 |
>20 μM
Compound: ursolic acid
|
Antiproliferative activity against mouse +SA mammary epithelial cells after 4 days by MTT assay
Antiproliferative activity against mouse +SA mammary epithelial cells after 4 days by MTT assay
|
[PMID: 18826277] |
| FaDu | EC50 |
14.2 μM
Compound: 2; UA
|
Cytotoxicity against human FADU cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
Cytotoxicity against human FADU cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
|
[PMID: 27149037] |
| FaDu | EC50 |
14.2 μM
Compound: UA
|
Cytotoxicity against human FADU cells after 96 hrs by SRB assay
Cytotoxicity against human FADU cells after 96 hrs by SRB assay
|
[PMID: 26750249] |
| Fibroblast | IC50 |
3.5 μM
Compound: ursolic acid
|
Toxicity against human dermal fibroblasts
Toxicity against human dermal fibroblasts
|
[PMID: 19036585] |
| GES1 | IC50 |
93.83 μM
Compound: UA, Ursolic acid
|
Cytotoxicity against human GES-1 cells incubated for 48 hrs by MTT assay
Cytotoxicity against human GES-1 cells incubated for 48 hrs by MTT assay
|
[PMID: 21664827] |
| H9 | EC50 |
2 μg/mL
Compound: 6
|
Cytotoxicity against mock-infected human H9 cells after 4 days
Cytotoxicity against mock-infected human H9 cells after 4 days
|
[PMID: 9748372] |
| H9 | EC50 |
4.4 μM
Compound: 6
|
Cytotoxicity against mock-infected human H9 cells
Cytotoxicity against mock-infected human H9 cells
|
[PMID: 11141100] |
| H9 | IC50 |
14.3 μM
Compound: 6
|
Antiviral activity against HIV1 3B isolate replication in human H9 cells assessed as decrease in viral p24 level after 4 days
Antiviral activity against HIV1 3B isolate replication in human H9 cells assessed as decrease in viral p24 level after 4 days
|
[PMID: 11141100] |
| H9 | IC50 |
6.5 μg/mL
Compound: 6
|
Antiviral activity against HIV1 3B in human H9 cells after 4 days by p24 antigen ELISA
Antiviral activity against HIV1 3B in human H9 cells after 4 days by p24 antigen ELISA
|
[PMID: 9748372] |
| HCT-116 | IC50 |
17.7 μM
Compound: UA
|
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay
|
[PMID: 34352711] |
| HCT-116 | IC50 |
19 μM
Compound: UA
|
Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 31771799] |
| HCT-116 | IC50 |
38.78 μM
Compound: UA
|
Cytotoxicity against human HCT116 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human HCT116 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 25841199] |
| HCT-116 | IC50 |
42 μM
Compound: 1
|
Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
|
[PMID: 26854375] |
| HCT-116 | IC50 |
42 μM
Compound: 4
|
Growth inhibition of human HCT116 cells after 48 hrs by sulforhodamine-B assay
Growth inhibition of human HCT116 cells after 48 hrs by sulforhodamine-B assay
|
[PMID: 23811086] |
| HEK293 | IC50 |
1.9 μM
Compound: 9
|
Inhibition of human recombinant 11beta-HSD1 expressed in HEK293 cells assessed as reduction of cortisone to cortisol conversion by scintillation counting
Inhibition of human recombinant 11beta-HSD1 expressed in HEK293 cells assessed as reduction of cortisone to cortisol conversion by scintillation counting
|
[PMID: 20100662] |
| HeLa | IC50 |
>10 μM
Compound: 1, Ursolic acid,UA
|
Antiproliferative activity against human HeLa cells after 96 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 96 hrs by MTT assay
|
[PMID: 19091579] |
| HeLa | IC50 |
>40 μM
Compound: 1; UA
|
Cytotoxic activity against human HeLa cells after 72 hrs by MTT assay
Cytotoxic activity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 28733083] |
| HeLa | IC50 |
11.1 μg/mL
Compound: 1
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
|
[PMID: 30057155] |
| HeLa | IC50 |
14.31 μM
Compound: UA
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method
|
[PMID: 38039788] |
| HeLa | IC50 |
33.1 μM
Compound: UA 5
|
Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 28754470] |
| HeLa | IC50 |
33.12 μM
Compound: 1, UA, Ursolic acid
|
Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
|
[PMID: 21514015] |
| HeLa | IC50 |
64.48 μM
Compound: UA
|
Antiproliferative activity against human HeLa cells after 48 hrs by CCK-8 assay
Antiproliferative activity against human HeLa cells after 48 hrs by CCK-8 assay
|
[PMID: 26343825] |
| Hep 3B2 | IC50 |
23.8 μM
Compound: UA
|
Cytotoxicity against human Hep3B cells assessed as reduction in cell viability after 24 hrs by MTT assay
Cytotoxicity against human Hep3B cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 31006525] |
| Hep 3B2 | IC50 |
23.8 μM
Compound: UA; 1
|
Cytotoxicity against human Hep3B cells assessed as reduction in cell viability after 24 hrs in normoxic condition by MTT assay
Cytotoxicity against human Hep3B cells assessed as reduction in cell viability after 24 hrs in normoxic condition by MTT assay
|
[PMID: 30728113] |
| HepG2 | CC50 |
113.62 μM
Compound: UA
|
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 29326018] |
| HepG2 | EC50 |
41.31 μM
Compound: UA
|
Agonist activity at human recombinant PPARalpha expressed in HepG2 cells co-transfected with pGL3-PPRE3-TK-luc reporter assessed as beta-galactosidase activity after 24 hrs by luciferase based transactivation assay
Agonist activity at human recombinant PPARalpha expressed in HepG2 cells co-transfected with pGL3-PPRE3-TK-luc reporter assessed as beta-galactosidase activity after 24 hrs by luciferase based transactivation assay
|
[PMID: 21855333] |
| HepG2 | IC50 |
>10 μM
Compound: 22
|
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 27797185] |
| HepG2 | IC50 |
>20 μM
Compound: Ursolic acid
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT colorimetric based assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT colorimetric based assay
|
[PMID: 38107170] |
| HepG2 | IC50 |
10.84 μM
Compound: UA
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method
|
[PMID: 38039788] |
| HepG2 | IC50 |
14.49 μM
Compound: UA
|
Cytotoxicity against human HepG2 cells assessed as inhibition of cell viability measured after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as inhibition of cell viability measured after 72 hrs by MTT assay
|
[PMID: 37742398] |
| HepG2 | IC50 |
145 μM
Compound: 3
|
Cytotoxicity against human Hep G2 cells after 48 hrs by WST-8 assay
Cytotoxicity against human Hep G2 cells after 48 hrs by WST-8 assay
|
[PMID: 15730243] |
| HepG2 | IC50 |
15 μM
Compound: 1
|
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 22959527] |
| HepG2 | IC50 |
30.21 μM
Compound: UA
|
Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 25841199] |
| HepG2 | IC50 |
40.2 μM
Compound: 9
|
Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by neutral red assay
Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by neutral red assay
|
[PMID: 28318944] |
| HepG2 | IC50 |
42.9 μM
Compound: 4a
|
Cytotoxicity against human HepG2 cells
Cytotoxicity against human HepG2 cells
|
[PMID: 25442310] |
| HepG2 | IC50 |
53.4 μM
Compound: 1, UA, Ursolic acid
|
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 22370266] |
| HepG2 | IC50 |
53.4 μM
Compound: UA 5
|
Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 28754470] |
| HepG2 | IC50 |
53.42 μM
Compound: UA, Ursolic acid
|
Cytotoxicity against human HepG2 cells incubated for 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells incubated for 48 hrs by MTT assay
|
[PMID: 21664827] |
| HepG2 | IC50 |
68.8 μM
Compound: UA 5
|
Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 28754470] |
| HepG2 | IC50 |
68.82 μM
Compound: 1, UA, Ursolic acid
|
Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
|
[PMID: 21514015] |
| HepG2 2.2.15 | CC50 |
1537.8 μM
Compound: A1; UA
|
Cytotoxicity against human HepG2.215 cells assessed as reduction in cell viability after 3 days by MTT assay
Cytotoxicity against human HepG2.215 cells assessed as reduction in cell viability after 3 days by MTT assay
|
[PMID: 29627260] |
| HL-60 | IC50 |
>40 μM
Compound: 1; UA
|
Growth inhibition of human HL60 cells after 48 hrs by MTT assay
Growth inhibition of human HL60 cells after 48 hrs by MTT assay
|
[PMID: 28073673] |
| HL-60 | IC50 |
21 μM
Compound: UA
|
Cytotoxicity against human HL60 cells after 96 hrs by MTT assay
Cytotoxicity against human HL60 cells after 96 hrs by MTT assay
|
[PMID: 15620242] |
| HL-60 | IC50 |
8.7 μg/mL
Compound: 8
|
Cytotoxicity against human HL60 cells after 24 hrs by MTT assay
Cytotoxicity against human HL60 cells after 24 hrs by MTT assay
|
[PMID: 19534471] |
| HL-60 | IC50 |
9.5 μM
Compound: UA
|
Antiproliferative activity against human HL-60 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis
Antiproliferative activity against human HL-60 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis
|
[PMID: 34352711] |
| HMEC | IC50 |
39.3 μM
Compound: UA 5
|
Cytotoxicity in human HMEC cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
Cytotoxicity in human HMEC cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
|
[PMID: 28754470] |
| HMV-2 cell line | CC50 |
145.9 μM
Compound: 5
|
Cytotoxicity against HMVII cells assessed as reduction in cell viability after 24 hrs by MTT assay
Cytotoxicity against HMVII cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 27020521] |
| HMV-2 cell line | CC50 |
69.5 μM
Compound: 5
|
Cytotoxicity against HMVII cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against HMVII cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 27020521] |
| HT-29 | EC50 |
10.6 μM
Compound: 1
|
Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
|
[PMID: 28033541] |
| HT-29 | EC50 |
10.6 μM
Compound: 2; UA
|
Cytotoxicity against human HT-29 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
Cytotoxicity against human HT-29 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
|
[PMID: 27149037] |
| HT-29 | EC50 |
10.6 μM
Compound: UA
|
Cytotoxicity against human HT-29 cells assessed as cell survival after 96 hrs by SRB assay
Cytotoxicity against human HT-29 cells assessed as cell survival after 96 hrs by SRB assay
|
[PMID: 26177446] |
| HT-29 | EC50 |
10.6 μM
Compound: UA
|
Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
|
[PMID: 26750249] |
| HT-29 | EC50 |
10.6 μM
Compound: UA
|
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
|
[PMID: 31718946] |
| HT-29 | IC50 |
11.1 μg/mL
Compound: 1
|
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
|
[PMID: 30057155] |
| HT-29 | IC50 |
25.3 μM
Compound: 1, UA, Ursolic acid
|
Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
|
[PMID: 22370266] |
| HT-29 | IC50 |
25.3 μM
Compound: UA 5
|
Cytotoxicity in human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
Cytotoxicity in human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
|
[PMID: 28754470] |
| HT-29 | IC50 |
26.31 μM
Compound: UA, Ursolic acid
|
Cytotoxicity against human HT-29 cells incubated for 48 hrs by MTT assay
Cytotoxicity against human HT-29 cells incubated for 48 hrs by MTT assay
|
[PMID: 21664827] |
| HT-29 | IC50 |
3.5 μM
Compound: 1
|
Inhibition of mitochondrial membrane potential in human HT-29 cells after 3 hrs by JC-1 staining based fluorescence assay
Inhibition of mitochondrial membrane potential in human HT-29 cells after 3 hrs by JC-1 staining based fluorescence assay
|
[PMID: 30057155] |
| J774 | IC50 |
13.1 μM
Compound: 7
|
Cytotoxicity against mouse J774 cells by alamar blue assay
Cytotoxicity against mouse J774 cells by alamar blue assay
|
[PMID: 17637068] |
| K562 | IC50 |
10.2 μM
Compound: UA
|
Antiproliferative activity against human K562 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis
Antiproliferative activity against human K562 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis
|
[PMID: 34352711] |
| K562 | IC50 |
41.01 μM
Compound: 2; UA
|
Cytotoxicity against human K562 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human K562 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 31673307] |
| K562/Adr | IC50 |
38.06 μM
Compound: 2; UA
|
Cytotoxicity against human K562/ADR cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human K562/ADR cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 31673307] |
| KB | ED50 |
3.76 μg/mL
Compound: ursolic acid
|
Cytotoxicity against human KB cells by microassay
Cytotoxicity against human KB cells by microassay
|
[PMID: 2380724] |
| KB | ED50 |
8.3 μM
Compound: 3, UA
|
Cytotoxicity against human KB cells by sulforhodamine B assay
Cytotoxicity against human KB cells by sulforhodamine B assay
|
[PMID: 17591444] |
| KB | IC50 |
31.5 μM
Compound: 4a
|
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
|
[PMID: 25442310] |
| KB | IC50 |
31.8 μM
Compound: 9
|
Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by neutral red assay
Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by neutral red assay
|
[PMID: 28318944] |
| L02 | IC50 |
>100 μM
Compound: UA
|
Cytotoxicity against human HL7702 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human HL7702 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 25841199] |
| L02 | IC50 |
>50 μM
Compound: UA; 1
|
Cytotoxicity against human HL7702 cells after 48 hrs by MTT assay
Cytotoxicity against human HL7702 cells after 48 hrs by MTT assay
|
[PMID: 30108853] |
| L02 | IC50 |
58.37 μM
Compound: 2; UA
|
Cytotoxicity against human LO2 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human LO2 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 31673307] |
| L02 | IC50 |
8.85 μM
Compound: UA
|
Cytotoxicity against human HL7702 cells assessed as inhibition of cell viability measured after 72 hrs by MTT assay
Cytotoxicity against human HL7702 cells assessed as inhibition of cell viability measured after 72 hrs by MTT assay
|
[PMID: 37742398] |
| Lewis lung carcinoma cell line | IC50 |
23.37 μM
Compound: 2; UA
|
Cytotoxicity activity against mouse LLC cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity activity against mouse LLC cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 30433783] |
| LN-229 | IC50 |
47.4 μM
Compound: UA
|
Antiproliferative activity against human LN-229 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay
Antiproliferative activity against human LN-229 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay
|
[PMID: 34352711] |
| Lu1 | IC50 |
11.5 μM
Compound: 9
|
Cytotoxicity against human Lu1 cells assessed as growth inhibition after 72 hrs by neutral red assay
Cytotoxicity against human Lu1 cells assessed as growth inhibition after 72 hrs by neutral red assay
|
[PMID: 28318944] |
| MCF7 | EC50 |
12.7 μM
Compound: 1
|
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
|
[PMID: 28033541] |
| MCF7 | EC50 |
12.7 μM
Compound: 2; UA
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
|
[PMID: 27149037] |
| MCF7 | EC50 |
12.7 μM
Compound: UA
|
Cytotoxicity against human MCF7 cells assessed as cell survival after 96 hrs by SRB assay
Cytotoxicity against human MCF7 cells assessed as cell survival after 96 hrs by SRB assay
|
[PMID: 26177446] |
| MCF7 | EC50 |
12.7 μM
Compound: UA
|
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
|
[PMID: 26750249] |
| MCF7 | EC50 |
12.7 μM
Compound: UA
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
|
[PMID: 31718946] |
| MCF7 | GI50 |
21 μM
Compound: UA 5
|
Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
|
[PMID: 28754470] |
| MCF7 | IC50 |
>30 μM
Compound: Ursolic acid
|
Cytotoxicity against human adriamycin- resistant MCF7 cells by WST-1 assay
Cytotoxicity against human adriamycin- resistant MCF7 cells by WST-1 assay
|
[PMID: 19836230] |
| MCF7 | IC50 |
>30 μM
Compound: Ursolic acid
|
Cytotoxicity against human MCF7 cells by WST-1 assay
Cytotoxicity against human MCF7 cells by WST-1 assay
|
[PMID: 19836230] |
| MCF7 | IC50 |
>30 μM
Compound: Ursolic acid
|
Cytotoxicity against human tamoxifen-resistant MCF7 cells by WST-1 assay
Cytotoxicity against human tamoxifen-resistant MCF7 cells by WST-1 assay
|
[PMID: 19836230] |
| MCF7 | IC50 |
>30 μM
Compound: UA
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method
|
[PMID: 38039788] |
| MCF7 | IC50 |
12.3 μM
Compound: 1
|
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 22959527] |
| MCF7 | IC50 |
25.05 μM
Compound: Ursolic acid
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay
|
[PMID: 38889607] |
| MCF7 | IC50 |
37 μM
Compound: 1
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 26854375] |
| MCF7 | IC50 |
37 μM
Compound: 4
|
Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine-B assay
Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine-B assay
|
[PMID: 23811086] |
| MCF7 | IC50 |
44.84 μM
Compound: UA
|
Antiproliferative activity against human MCF7 cells after 48 hrs by CCK-8 assay
Antiproliferative activity against human MCF7 cells after 48 hrs by CCK-8 assay
|
[PMID: 26343825] |
| MCF7 | IC50 |
6.6 μM
Compound: 22
|
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 27797185] |
| MCF7 | IC50 |
70.12 μM
Compound: 2; UA
|
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 31673307] |
| MCF7 | IC50 |
9.3 μM
Compound: 9
|
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by neutral red assay
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by neutral red assay
|
[PMID: 28318944] |
| MDA-MB-231 | GI50 |
11.1 μM
Compound: UA 5
|
Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
|
[PMID: 28754470] |
| MDA-MB-231 | IC50 |
>30 μM
Compound: Ursolic acid
|
Cytotoxicity against human MDA-MB-231 cells by WST-1 assay
Cytotoxicity against human MDA-MB-231 cells by WST-1 assay
|
[PMID: 19836230] |
| MDA-MB-231 | IC50 |
>40 μM
Compound: 1; UA
|
Cytotoxic activity against human MDA-MB-231 cells after 72 hrs by MTT assay
Cytotoxic activity against human MDA-MB-231 cells after 72 hrs by MTT assay
|
[PMID: 28733083] |
| MDA-MB-231 | IC50 |
13.97 μM
Compound: UA
|
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method
|
[PMID: 38039788] |
| MDA-MB-231 | IC50 |
5.9 μM
Compound: 1
|
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
|
[PMID: 30057155] |
| MDA-MB-231 | IC50 |
70.27 μM
Compound: 2; UA
|
Cytotoxicity activity against human MDA-MB-231 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity activity against human MDA-MB-231 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 30433783] |
| MDA-MB-435 | IC50 |
13.1 μg/mL
Compound: 1
|
Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
|
[PMID: 30057155] |
| MGC-803 | IC50 |
>200 μM
Compound: UA
|
Cytotoxicity against human MGC-803 cells assessed as inhibition of cell viability measured after 72 hrs by MTT assay
Cytotoxicity against human MGC-803 cells assessed as inhibition of cell viability measured after 72 hrs by MTT assay
|
[PMID: 37742398] |
| MGC-803 | IC50 |
24.32 μM
Compound: 1, UA, Ursolic acid
|
Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay
Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay
|
[PMID: 23124210] |
| MGC-803 | IC50 |
27.08 μM
Compound: UA
|
Cytotoxicity against human MGC803 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human MGC803 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 25841199] |
| MGC-803 | IC50 |
27.58 μM
Compound: UA; 1
|
Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay
Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay
|
[PMID: 30108853] |
| MIA PaCa-2 | IC50 |
10.4 μM
Compound: 1
|
Cytotoxicity against human MIAPaCa2 cells after 72 hrs by MTT assay
Cytotoxicity against human MIAPaCa2 cells after 72 hrs by MTT assay
|
[PMID: 22959527] |
| NCI-H460 | IC50 |
14.8 μM
Compound: 1; UA
|
Cytotoxicity against human NCI-H460 cells expressing CTR5 gene assessed as reduction in cell viability measured after 72 hrs by CellTiter-Blue cell viability assay
Cytotoxicity against human NCI-H460 cells expressing CTR5 gene assessed as reduction in cell viability measured after 72 hrs by CellTiter-Blue cell viability assay
|
[PMID: 27484517] |
| NCI-H460 | IC50 |
16.2 μM
Compound: UA
|
Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay
Antiproliferative activity against human NCI-H460 cells assessed as inhibition of cell viability measured after 72 hrs by colorimetric MTS viability assay
|
[PMID: 34352711] |
| NCI-H460 | IC50 |
21.1 μM
Compound: 1; UA
|
Cytotoxicity against human LKB1-positive NCI-H460 cells assessed as reduction in cell viability measured after 72 hrs by CellTiter-Blue cell viability assay
Cytotoxicity against human LKB1-positive NCI-H460 cells assessed as reduction in cell viability measured after 72 hrs by CellTiter-Blue cell viability assay
|
[PMID: 27484517] |
| NCI-H460 | IC50 |
30.8 μM
Compound: 1; UA
|
Cytotoxicity against human NCI-H460 spheroids expressing CTR5 gene assessed as reduction in cell viability measured after 96 hrs by CellTiter-Glo luminescence viability assay
Cytotoxicity against human NCI-H460 spheroids expressing CTR5 gene assessed as reduction in cell viability measured after 96 hrs by CellTiter-Glo luminescence viability assay
|
[PMID: 27484517] |
| NCI-H460 | IC50 |
32.17 μM
Compound: UA; 1
|
Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay
Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay
|
[PMID: 30108853] |
| NCI-N87 | IC50 |
4.2 μM
Compound: 22
|
Cytotoxicity against human NCI-N87 cells after 72 hrs by MTT assay
Cytotoxicity against human NCI-N87 cells after 72 hrs by MTT assay
|
[PMID: 27797185] |
| Neutrophil | IC50 |
0.29 μg/mL
Compound: Ursolic acid
|
Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced superoxide anion release
Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced superoxide anion release
|
[PMID: 21106454] |
| Neutrophil | IC50 |
0.31 μg/mL
Compound: Ursolic acid
|
Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced elastase release
Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced elastase release
|
[PMID: 21106454] |
| Neutrophil | IC50 |
0.6 μg/mL
Compound: 21
|
Anti-inflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide anion generation by measuring superoxide dismutase SOD-inhibitable ferricytochrome c reduction incubated for 5 mins before fMLP/CB stimulation for 3 mins
Anti-inflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide anion generation by measuring superoxide dismutase SOD-inhibitable ferricytochrome c reduction incubated for 5 mins before fMLP/CB stimulation for 3 mins
|
[PMID: 28218000] |
| Neutrophil | IC50 |
0.8 μg/mL
Compound: 21
|
Anti-inflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release pre-incubated for 5 mins before fMLP/CB stimulation using MeO-Suc-Ala-Ala-Pro-Val-pnitroanilide as substrate
Anti-inflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release pre-incubated for 5 mins before fMLP/CB stimulation using MeO-Suc-Ala-Ala-Pro-Val-pnitroanilide as substrate
|
[PMID: 28218000] |
| Neutrophil | IC50 |
2.79 μg/mL
Compound: 5
|
Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced superoxide-anion generation incubated for 5 mins prior to FMLP/CB-challenge measured after 10 mins by spectrophotometry
Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced superoxide-anion generation incubated for 5 mins prior to FMLP/CB-challenge measured after 10 mins by spectrophotometry
|
[PMID: 22429052] |
| Neutrophil | IC50 |
5.21 μg/mL
Compound: 5
|
Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced elastase release using Meo-Suc-Ala-Ala-Pro-Val-p-nitroanilide as substrate incubated for 5 mins prior to FMLP/CB-challenge by spectrophotometry
Antiinflammatory activity in human neutrophils assessed as inhibition of FMLP/CB-induced elastase release using Meo-Suc-Ala-Ala-Pro-Val-p-nitroanilide as substrate incubated for 5 mins prior to FMLP/CB-challenge by spectrophotometry
|
[PMID: 22429052] |
| NIH3T3 | EC50 |
13.1 μM
Compound: UA
|
Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
|
[PMID: 31718946] |
| NIH3T3 | EC50 |
18.7 μM
Compound: 1
|
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
|
[PMID: 28033541] |
| NIH3T3 | EC50 |
18.7 μM
Compound: 2; UA
|
Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
|
[PMID: 27149037] |
| NIH3T3 | EC50 |
18.7 μM
Compound: UA
|
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
|
[PMID: 26750249] |
| NTUB1 | IC50 |
29.44 μM
Compound: 1
|
Cytotoxicity against human NTUB1 cells after 72 hrs by MTT assay
Cytotoxicity against human NTUB1 cells after 72 hrs by MTT assay
|
[PMID: 19758808] |
| OVCAR-3 | IC50 |
12.9 μg/mL
Compound: 1
|
Cytotoxicity against human OVCAR3 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
Cytotoxicity against human OVCAR3 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
|
[PMID: 30057155] |
| PANC-1 | IC50 |
14.9 μM
Compound: 1
|
Cytotoxicity against human PANC1 cells after 72 hrs by MTT assay
Cytotoxicity against human PANC1 cells after 72 hrs by MTT assay
|
[PMID: 22959527] |
| PANC-1 | IC50 |
58.03 μM
Compound: 2; UA
|
Cytotoxicity activity against human PANC1 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity activity against human PANC1 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 30433783] |
| PC-3 | IC50 |
>10 μg/mL
Compound: 5
|
Antiproliferative activity against human PC3 cells after 48 hrs by SRB assay
Antiproliferative activity against human PC3 cells after 48 hrs by SRB assay
|
[PMID: 22429052] |
| PC-3 | IC50 |
20.8 μM
Compound: 1
|
Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
|
[PMID: 22959527] |
| PC-3 | IC50 |
22.3 μM
Compound: 1, UA, Ursolic acid
|
Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
Cytotoxicity against human PC3 cells after 48 hrs by MTT assay
|
[PMID: 22370266] |
| PC-3 | IC50 |
22.3 μM
Compound: UA 5
|
Cytotoxicity in human PC3 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity in human PC3 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 28754470] |
| Platelet | IC50 |
>50 μg/mL
Compound: Ursolic acid
|
Antiaggregatory activity in human platelets assessed as inhibition of thrombin-induced platelet aggregation by aggregometry
Antiaggregatory activity in human platelets assessed as inhibition of thrombin-induced platelet aggregation by aggregometry
|
[PMID: 21106454] |
| Platelet | IC50 |
34.53 μg/mL
Compound: Ursolic acid
|
Antiaggregatory activity in human platelets assessed as inhibition of collagen-induced platelet aggregation by aggregometry
Antiaggregatory activity in human platelets assessed as inhibition of collagen-induced platelet aggregation by aggregometry
|
[PMID: 21106454] |
| PLC-PRF-5 | ED50 |
3.89 μg/mL
Compound: ursolic acid
|
Cytotoxicity against human PLC/PRF/5 cells by microassay
Cytotoxicity against human PLC/PRF/5 cells by microassay
|
[PMID: 2380724] |
| RAW264.7 | IC50 |
>50 μM
Compound: 1
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess method
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess method
|
[PMID: 22079762] |
| RAW264.7 | IC50 |
13.8 μM
Compound: UA
|
Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production incubated for 2 hrs followed by LPS stimulation for 20 hrs by Griess reagent based assay
Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production incubated for 2 hrs followed by LPS stimulation for 20 hrs by Griess reagent based assay
|
[PMID: 35175765] |
| RAW264.7 | IC50 |
46.9 μM
Compound: Ursolic acid
|
Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells by Griess method
Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells by Griess method
|
[PMID: 14510614] |
| RAW264.7 | IC50 |
58.5 μM
Compound: Ursolic acid
|
Cytotoxicity against LPS-stimulated mouse RAW264.7 cells by Griess method
Cytotoxicity against LPS-stimulated mouse RAW264.7 cells by Griess method
|
[PMID: 14510614] |
| Sf21 | IC50 |
>40 μM
Compound: 23
|
Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as decrease in PGE2 formation using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis
Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as decrease in PGE2 formation using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis
|
[PMID: 31774676] |
| SGC-7901 | IC50 |
>20 μM
Compound: Ursolic acid
|
Cytotoxicity against human SGC-7901 cells assessed as reduction in cell viability measured after 48 hrs by MTT colorimetric assay
Cytotoxicity against human SGC-7901 cells assessed as reduction in cell viability measured after 48 hrs by MTT colorimetric assay
|
[PMID: 38107170] |
| SH-SY5Y | IC50 |
54.62 μM
Compound: 1, UA, Ursolic acid
|
Cytotoxicity against human SH-SY5Y cells after 24 hrs by MTT assay
Cytotoxicity against human SH-SY5Y cells after 24 hrs by MTT assay
|
[PMID: 21514015] |
| SK-OV-3 | IC50 |
>10 μM
Compound: 1, Ursolic acid,UA
|
Antiproliferative activity against human SKOV3 cells after 96 hrs by MTT assay
Antiproliferative activity against human SKOV3 cells after 96 hrs by MTT assay
|
[PMID: 19091579] |
| SMMC-7721 | IC50 |
>40 μM
Compound: 1; UA
|
Cytotoxic activity against human SMMC7721 cells after 72 hrs by MTT assay
Cytotoxic activity against human SMMC7721 cells after 72 hrs by MTT assay
|
[PMID: 28733083] |
| T-24 | IC50 |
17.76 μM
Compound: UA
|
Cytotoxicity against human T24 cells assessed as inhibition of cell viability measured after 72 hrs by MTT assay
Cytotoxicity against human T24 cells assessed as inhibition of cell viability measured after 72 hrs by MTT assay
|
[PMID: 37742398] |
| T-24 | IC50 |
29.29 μM
Compound: UA
|
Cytotoxicity against human T24 cells assessed as cell viability after 48 hrs by MTT assay
Cytotoxicity against human T24 cells assessed as cell viability after 48 hrs by MTT assay
|
[PMID: 25841199] |
| T-24 | IC50 |
29.29 μM
Compound: UA; 1
|
Cytotoxicity against human T24 cells after 48 hrs by MTT assay
Cytotoxicity against human T24 cells after 48 hrs by MTT assay
|
[PMID: 30108853] |
| THP-1 | IC50 |
9.1 μM
Compound: 1
|
Cytotoxicity against human THP1 cells after 48 hrs by MTT assay
Cytotoxicity against human THP1 cells after 48 hrs by MTT assay
|
[PMID: 26854375] |
| THP-1 | IC50 |
9.1 μM
Compound: 4
|
Growth inhibition of human THP1 cells after 48 hrs by sulforhodamine-B assay
Growth inhibition of human THP1 cells after 48 hrs by sulforhodamine-B assay
|
[PMID: 23811086] |
| Vero | CC50 |
31.9 μM
Compound: 5
|
Cytotoxicity against african green monkey Vero cells assessed as reduction in cell viability after 24 hrs by MTT assay
Cytotoxicity against african green monkey Vero cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 27020521] |
| Vero | CC50 |
35.9 μM
Compound: 5
|
Cytotoxicity against african green monkey Vero cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against african green monkey Vero cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 27020521] |
| Vero | CC50 |
99.91 μM
Compound: UA
|
Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay
Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay
|
[PMID: 29326018] |
| WI-38 | IC50 |
1.8 μM
Compound: 3
|
Cytotoxicity against human WI 38 cells after 48 hrs by WST-8 assay
Cytotoxicity against human WI 38 cells after 48 hrs by WST-8 assay
|
[PMID: 15730243] |
| WI-38 VA13 | IC50 |
93.6 μM
Compound: 3
|
Cytotoxicity against human VA13 cells after 48 hrs by WST-8 assay
Cytotoxicity against human VA13 cells after 48 hrs by WST-8 assay
|
[PMID: 15730243] |
| Z-138 | IC50 |
9.8 μM
Compound: UA
|
Antiproliferative activity against human Z138 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis
Antiproliferative activity against human Z138 cells assessed as inhibition of cell viability measured after 72 hrs by real-time IncuCyte proliferation analysis
|
[PMID: 34352711] |
Ursolic acid induces phosphorylation of AMP-activated protein kinase alpha (AMPKα) and suppressed the protein expression of DNA methyltransferase 1 (DNMT1) in the dose-dependent manner[1].
The combination of Ursolic acid (0.5 μM) and Leucine (10 μM) prove to be the most effective in promoting myogenic differentiation. The combination of Ursolic acid and Leucine significantly increase CK activity than treatment with either agent alone. The level of myosin heavy chain, a myogenic differentiation marker protein, is also enhanced by the combination of Ursolic acid and Leucine[2].
Ursolic acid efficiently induces apoptosis, possibly via the downregulation of B-cell lymphoma 2 (Bcl-2), the upregulation of Bcl-2-associated X protein and the proteolytic activation of caspase-3. Furthermore, the activation of p38 mitogen-activated protein kinase and c-Jun N-terminal kinase is increased by the administration of ursolic acid. In addition, Ursolic acid significantly suppresses the invasive phenotype of the SNU-484 cells and significantly decreases the expression of matrix metalloproteinase (MMP)-2[3].
Ursolic acid (UA) potently induces the apoptosis of gastric cancer SGC-7901 cells. Further mechanistic studies revealed that the ROCK1/PTEN signaling pathway plays a critical role in Ursolic acid-mediated mitochondrial translocation of cofilin-1 and apoptosis[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 77-52-1
-
Appearance Solid
-
Molecular Weight 456.70
-
Formula C30H48O3
-
Color White to off-white
-
SMILES
CC1(C)[C@@H](O)CC[C@]2(C)[C@@]3([H])CC=C4[C@]5([H])[C@@H](C)[C@H](C)CC[C@@](C(O)=O)5CC[C@](C)4[C@@](C)3CC[C@@]12[H]
-
Synonyms
Prunol; Urson; Malol
-
Structure Classification
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (20)
-
Journal Impact Factor
-
Most Recent
-
-
J Hazard Mater
Ammonia-induced exosomal miRNA disrupts autophagy and promotes lung injury: Therapeutic potential of natural compounds. [Abstract]2026 Mar 15:506:141417. PMID: 41775203 -
Int J Biol Sci
Exploration of diagnostic biomarkers, microenvironment characteristics, and ursolic acid's therapeutic effect for benign prostate hyperplasia. [Abstract]2023 Aug 15;19(13):4242-4258. PMID: 37705744
Ursolic acid purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2023 Aug 15;19(13):4242-4258. [Abstract]
The CCK-8 experiment results showed that Ursolic acid (0, 10, 20, 30 μmol/L, 24 h) inhibited the viability of BPH-1 cells in a concentration limitation-dependent manner.
Ursolic acid purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2023 Aug 15;19(13):4242-4258. [Abstract]
Ursolic acid (5 mg/kg, p.o.) treatment led to significant improvement in the pathological status of the BPH prostate, with the HE staining showing an overall regular prostate glandular lumen, mostly clear glandular arrangement, single-layer columnar epithelial cells of acini, no obvious proliferation in the stromal tissue, and no obvious inflammatory cell infiltration.
Ursolic acid purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2023 Aug 15;19(13):4242-4258. [Abstract]
After treating cells with different concentrations of Ursolic acid (0. 10. 20. 30.μmol/L, 24 h), the expression of apoptosis-related proteins Caspase3 and Bax gradually increased, while the expression of anti-apoptotic protein Bcl-2 gradually decreased, as detected by WB experiments.
Ursolic acid purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2023 Aug 15;19(13):4242-4258. [Abstract]
Flow cytometry detected significant induction of BPH-1 cell apoptosis by Ursolic acid (0. 10. 20. 30.μmol/L, 24 h) treatment.
Ursolic acid purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2023 Aug 15;19(13):4242-4258. [Abstract]
Flow cytometry detected significant induction of BPH-1 cell cycle arrest by Ursolic acid (0. 10. 20. 30.μmol/L, 24 h) treatment.
-
Food Chem
Discovery of novel ascorbic acid derivatives and other metabolites in fruit of Rosa roxburghii Tratt through untargeted metabolomics and feature-based molecular networking. [Abstract]2023 Mar 30;405(Pt A):134807. PMID: 36370576 -
Cell Death Dis
Overexpression of homeodomain-interacting protein kinase 2 (HIPK2) attenuates sepsis-mediated liver injury by restoring autophagy. [Abstract]2018 Aug 28;9(9):847. PMID: 30154452
Ursolic acid purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2018 Aug 28;9(9):847. [Abstract]
HIPK2 expression is upregulated by treatments with 5 μM Resveratrol, 30 μM Aspirin, 10 μM Vitamin E, and 15 μM Ursolic acid for another 16 h after the LPS treatment, as analysed by western blotting.
-
Phytomedicine
Bruceantin inhibits the c-Myc/RL27A axis to suppress tumor progression in hepatocellular carcinoma. [Abstract]2025 Dec 24:150:157740. PMID: 41477978 -
Phytomedicine
Fangchinoline suppresses nasopharyngeal carcinoma progression by inhibiting SQLE to regulate the PI3K/AKT pathway dysregulation. [Abstract]2025 May:140:156484. PMID: 40090046 -
Brain Behav Immun
Protective effect of Indole-3-carbinol, an NF-κB inhibitor in experimental paradigm of Parkinson's disease: In silico and in vivo studies. [Abstract]2020 Nov;90:108-137. PMID: 32800927 -
PLoS Biol
2024 Jun 27;22(6):e3002672. PMID: 38935621 -
Int J Mol Sci
2026 Mar 11;27(6):2587. PMID: 41898448 -
Eur J Pharmacol
Antipruritic effect of ursolic acid through MRGPRX2/MrgprB2-dependent inhibition of mast cell degranulation and reduced TSLP production. [Abstract]2024 Aug 13:176896. PMID: 39147012 -
Int Immunopharmacol
Ursolic acid alleviates Kupffer cells pyroptosis in liver fibrosis by the NOX2/NLRP3 inflammasome signaling pathway. [Abstract]2022 Dec;113(Pt A):109321. PMID: 36252479 -
Cancers (Basel)
Ursolic Acid Alleviates Cancer Cachexia and Prevents Muscle Wasting via Activating SIRT1. [Abstract]2023 Apr 20;15(8):2378. PMID: 37190306 -
Sci Rep
Ursolic and oleanolic acids suppress MNNG induced malignant transformation of human gastric mucosal epithelium by regulating the PI3 K/AKT pathway. [Abstract]2025 Jul 1;15(1):21623. PMID: 40594240 -
-
J Immunol Res
Ursolic Acid Regulates Intestinal Microbiota and Inflammatory Cell Infiltration to Prevent Ulcerative Colitis. [Abstract]2021 Apr 30:2021:6679316. PMID: 34007853 -
Toxicon
Ursolic acid enhances radiosensitivity in esophageal squamous cell carcinoma by modulating p53/SLC7A11/GPX4 pathway-mediated ferroptosis. [Abstract]2025 Jan 7:108233. PMID: 39788329 -
-
bioRxiv
An efficient behavioral screening platform classifies natural products and other chemical cues according to their chemosensory valence in C. elegans. [Abstract]2024 Apr 3:2023.06.02.542933. PMID: 37333363 -
Solvent & Solubility
DMSO : 33.33 mg/mL (72.98 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Yie Y, et al. Ursolic acid inhibited growth of hepatocellular carcinoma HepG2 cells through AMPKα-mediated reduction of DNA methyltransferase 1. Mol Cell Biochem. 2014 Dec 30. [Content Brief]
[2]. Kim M, et al. The combination of ursolic acid and leucine potentiates the differentiation of C2C12 murine myoblasts through the mTOR signaling pathway. Int J Mol Med. 2015 Mar;35(3):755-62. [Content Brief]
[3]. Kim ES, et al. Ursolic acid inhibits the invasive phenotype of SNU-484 human gastric cancer cells. Oncol Lett. 2015 Feb;9(2):897-902. [Content Brief]
[4]. Li R, et al. Ursolic Acid Promotes Apoptosis of SGC-7901 Gastric Cancer Cells through ROCK/PTEN Mediated Mitochondrial Translocation of Cofilin-1. Asian Pac J Cancer Prev. 2014;15(22):9593-7. [Content Brief]
[5]. Hu Z, et al. Ursolic acid improves survival and attenuates lung injury in septic rats induced by cecal ligation and puncture. J Surg Res. 2014 Oct 22. pii: S0022-4804(14)00967-6. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1896 mL | 10.9481 mL | 21.8962 mL | 54.7405 mL |
| 5 mM | 0.4379 mL | 2.1896 mL | 4.3792 mL | 10.9481 mL | |
| 10 mM | 0.2190 mL | 1.0948 mL | 2.1896 mL | 5.4741 mL | |
| 15 mM | 0.1460 mL | 0.7299 mL | 1.4597 mL | 3.6494 mL | |
| 20 mM | 0.1095 mL | 0.5474 mL | 1.0948 mL | 2.7370 mL | |
| 25 mM | 0.0876 mL | 0.4379 mL | 0.8758 mL | 2.1896 mL | |
| 30 mM | 0.0730 mL | 0.3649 mL | 0.7299 mL | 1.8247 mL | |
| 40 mM | 0.0547 mL | 0.2737 mL | 0.5474 mL | 1.3685 mL | |
| 50 mM | 0.0438 mL | 0.2190 mL | 0.4379 mL | 1.0948 mL | |
| 60 mM | 0.0365 mL | 0.1825 mL | 0.3649 mL | 0.9123 mL |